Introduction

Investing in clinical-stage biotechnology companies is a high-stakes endeavor characterized by extreme volatility, scientific breakthroughs, and regulatory hurdles. Few tickers capture this intense risk-reward dynamic as vividly as vxrt stock (Vaxart, Inc.). Known for its ambitious mission to replace traditional needle-based immunizations with a simple, room-temperature-stable oral pill, Vaxart is currently navigating one of the most critical years in its corporate history.

In 2026, Vaxart stands at a fascinating crossroads. Having transitioned from the Nasdaq to the Over-The-Counter (OTCQX) market in late 2025, the company is pushing hard to prove the commercial and clinical viability of its proprietary mucosal vaccine platform. With massive clinical trials fully enrolled, a lucrative global partnership with Dynavax Technologies, and a high-stakes proxy contest scheduled for July 2026, investors are searching for clarity: is VXRT stock a groundbreaking value opportunity at its current sub-$1.00 valuation, or is it a speculative trap?

This comprehensive guide delivers a deep, objective analysis of Vaxart’s current clinical landscape, its financial position, the technical mechanics of its platform, and the upcoming regulatory catalysts that will ultimately decide the fate of VXRT stock.

The OTCQX Reality: Why VXRT Stock Delisted from Nasdaq

To understand the current trading environment of VXRT stock, investors must first understand its recent regulatory and listing history—a topic that many generic financial blogs gloss over or present with outdated information.

On July 8, 2025, Vaxart’s common stock was officially suspended from trading on the Nasdaq Capital Market. This suspension followed a period of non-compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. Despite efforts by Vaxart’s management, including proposing a reverse stock split at their May 2025 annual meeting to regain compliance, the stock was eventually delisted. Nasdaq filed Form 25 in November 2025 to officially formalize the removal of the listing.

Following the Nasdaq delisting, Vaxart transitioned its share quotation to the OTCQX Best Market—the highest tier of the Over-The-Counter Markets Group. This transition allowed trading to continue under the ticker symbol VXRT without interruption.

For retail and institutional investors alike, trading on the OTCQX comes with distinct structural changes:

• Liquidity and Spreads: While the OTCQX represents the most transparent and regulated tier of the OTC market, trading volume is generally lower than on major national exchanges like Nasdaq. This can result in wider bid-ask spreads and higher intraday volatility.
• Institutional Constraints: Many mutual funds, pension funds, and institutional asset managers are governed by strict mandates that prohibit them from holding or purchasing OTC-quoted equities. Consequently, the delisting structurally reduced the institutional buying pressure on VXRT stock.
• State Blue Sky Laws: Because OTCQX-traded securities are not considered "covered securities" under the National Securities Markets Improvement Act of 1996, Vaxart must navigate state-by-state registration requirements, which can complicate broker-dealer transactions in certain jurisdictions.

Despite these headwinds, trading on the OTCQX has kept the stock highly accessible to retail investors. In mid-2026, VXRT stock is trading in a consolidated channel between $0.60 and $0.70. For speculative traders, this low share price represents a double-edged sword: a nominal price movement can yield massive percentage gains, but the risk of sudden downswings remains elevated.

Vaxart’s Proprietary VAAST Platform: The Tech Behind the Pill

At the heart of Vaxart's long-term investment thesis is its unique technology platform: Vector-Adjuvant-Antigen Standardized Technology (VAAST). This proprietary platform is designed to revolutionize how the human immune system is primed against infectious pathogens.

To appreciate Vaxart's differentiation, one must understand how traditional vaccines operate. Injectable vaccines—whether they are mRNA-based or protein subunit formulations—are designed to induce systemic immunity. They trigger the production of immunoglobulin G (IgG) antibodies in the bloodstream. While IgG antibodies are highly effective at preventing severe illness and systemic viral spread within the body, they do poorly at defending mucosal entry points: the nose, throat, mouth, and gastrointestinal tract.

Because most respiratory and enteric viruses (such as SARS-CoV-2 and norovirus) infect the body through mucosal membranes, traditional shots often fail to prevent infection and subsequent transmission. This is where Vaxart’s oral pill aims to change the paradigm.

Vaxart's VAAST platform combines three core components:

1. The Vector: A replication-defective Adenovirus Type 5 (Ad5) vector. This engineered virus is harmless; it cannot replicate or cause illness. Its sole purpose is to act as a highly efficient delivery truck, carrying the genetic instructions for the target antigen into the cells of the small intestine.
2. The Antigen: The specific genetic sequence of the target pathogen (such as the spike protein of SARS-CoV-2 or the VP1 protein of norovirus). Once inside the intestinal cells, these cells begin temporary production of the antigen, prompting an immune response.
3. The Adjuvant: A double-stranded RNA (dsRNA) molecule that acts as a potent molecular alarm. It stimulates Toll-like receptor 3 (TLR3) pathways, signaling to the immune system that a foreign threat is present. This adjuvant is critical because it stimulates both systemic IgG antibodies and mucosal immunoglobulin A (IgA) antibodies.

The oral formulation is packaged in an enteric-coated tablet. This specialized coating allows the tablet to pass entirely unscathed through the highly acidic environment of the stomach, only dissolving once it reaches the mild, near-neutral pH of the small intestine. By targeting the small intestine—which houses the vast majority of the body’s immune cells—Vaxart’s pill triggers a localized, mucosal-centric immune response that spills over to protect other mucosal tissues, including the respiratory tract.

From a commercial perspective, this pill formulation eliminates the massive logistical bottlenecks of the global vaccine supply chain. Vaxart's tablets are stable at room temperature, eliminating the need for expensive ultra-cold storage (cold chain) infrastructure. Furthermore, oral delivery removes the need for needles, medical syringes, and trained healthcare professionals to administer the doses, paving the way for self-administration and vastly higher global distribution efficiency.

The 2026 Clinical Roadmap: High-Stakes Catalysts

The valuation of VXRT stock is ultimately tied to the clinical progress of its two lead programs: the oral COVID-19 vaccine and the oral norovirus vaccine.

The Oral COVID-19 Program (VXA-CoV2-3.3)

Vaxart’s COVID-19 vaccine candidate is the subject of high-profile backing and partnerships. The company’s efforts are heavily supported by the Biomedical Advanced Research and Development Authority (BARDA) under the U.S. government’s Project NextGen initiative. To date, Vaxart has received $218.9 million in cumulative BARDA funding, which has drastically offset the enormous costs of running late-stage clinical trials.

The center of gravity for this program is an ongoing Phase 2b clinical trial. This study is a randomized, double-blind, comparator-controlled trial designed to evaluate Vaxart’s oral pill candidate (VXA-CoV2-3.3) directly against an FDA-approved injectable mRNA booster.

• The Sentinel Cohort: The trial includes a 400-person sentinel cohort (200 receiving the oral pill and 200 receiving the mRNA comparator). As of mid-2026, investors are eagerly awaiting the release of 12-month sentinel safety and immunogenicity data, which is targeted for early Q2 2026. While this cohort is not powered to definitively prove efficacy, positive safety results would be a major psychological win for the stock.
• The Main Cohort: The trial’s primary efficacy and safety readout will come from the main cohort of approximately 5,000 participants. This massive data set is designed to evaluate how the oral vaccine compares to mRNA injectables in terms of sustained, year-long protection. Vaxart anticipates reporting this highly anticipated primary efficacy data in late 2026 or early 2027.

Crucially, in November 2025, Vaxart scored a massive win by signing an exclusive worldwide license and collaboration agreement with Dynavax Technologies Corporation. Under this deal, Dynavax paid Vaxart an upfront fee of $25 million, alongside a $5 million equity investment at a premium to market. Dynavax received exclusive global rights to commercialize the oral COVID-19 vaccine candidate. Meanwhile, Vaxart retains operational and financial responsibility for the vaccine candidate through the completion of the Phase 2b trial and the subsequent End-of-Phase 2 meeting with the FDA. This partnership not only brought in much-needed non-dilutive capital but also provided major external validation of the VAAST platform’s commercial appeal from an established vaccine industry leader.

The Norovirus Vaccine Program: An Unmet Global Need

Norovirus is the leading cause of acute gastroenteritis worldwide, responsible for 685 million infections and 200,000 deaths annually. It represents a massive $60 billion global economic burden due to healthcare costs and lost productivity. Despite these shocking statistics, there is currently no approved norovirus vaccine on the market.

This massive clinical gap has made the norovirus space highly competitive, and Vaxart’s oral pill is positioned as a frontrunner. Its positioning was further enhanced by key developments among its competitors:

• In 2024, Takeda's spin-out, HilleVax, suffered a catastrophic Phase 2 trial failure, causing its stock to collapse and leaving a major vacuum in the norovirus vaccine market.
• Moderna’s mRNA-based candidate (mRNA-1403) entered Phase 3 in late 2024 but was quickly hit by an FDA clinical hold in early 2025 due to a case of Guillain-Barré Syndrome. Although the hold was eventually lifted, Moderna struggled with participant recruitment in the Southern Hemisphere, forcing it to shift trials northward in late 2025, delaying its timelines.

Vaxart, meanwhile, has made highly promising strides. In late 2025, the company presented positive head-to-head Phase 1 data comparing its second-generation oral norovirus constructs against its first-generation constructs. The results showed a stunning 25-fold increase in the GII.4 fecal IgA response and a 10-fold increase in the GI.1 fecal IgA response over baseline after a single tablet. Because fecal IgA was previously identified as a key correlate of protection in Vaxart’s Phase 2 challenge study (which demonstrated a 30% relative reduction in infection), these results represent a substantial step forward.

Furthermore, in Q1 2026, Vaxart published positive clinical results demonstrating that its oral norovirus vaccine candidate was safe and immunogenic in lactating women, showing passive transfer of antibodies to infants via breast milk. This is an essential clinical angle, as infants and young children are among the populations most vulnerable to severe norovirus-induced dehydration.

Vaxart's forward-looking strategy for norovirus is to advance to a Phase 2b safety and immunogenicity study and eventually a Phase 3 study. However, because its internal resources are prioritized on completing the COVID-19 trial, the initiation of these larger norovirus trials in 2026 is entirely contingent on securing a strategic business development partnership or additional non-dilutive external funding.

Financial Performance and Runway: Assessing the Dilution Risk

For clinical-stage biotechnology companies, financial management is a matter of survival. R&D-heavy companies must consistently balance their cash burn rates against clinical timelines to avoid catastrophic share dilution.

Vaxart’s Q1 2026 financial results, reported on May 7, 2026, paint a picture of a company in a significantly stronger position than in previous years:

• Revenue: Q1 2026 revenue jumped to $39.2 million, compared to $20.9 million in Q1 2025. This revenue was primarily driven by government contract recognition from the BARDA award, alongside milestone revenue recognized from the Dynavax collaboration agreement signed in late 2025.
• R&D and G&A Expenses: Research and development expenses were $29.4 million, a slight decrease from the $30.7 million spent in Q1 2025. This cost management was achieved through strategic head-count reductions and lower norovirus trial costs, which offset increased spending on the active COVID-19 Phase 2b trial. General and administrative expenses fell to $4.6 million, down from $5.1 million in the prior-year period.
• Profitability: Thanks to the frontloaded license revenues, Vaxart reported a rare net income of $5.2 million ($0.02 EPS) for the first quarter of 2026, a massive turnaround from the net loss of $15.6 million ($0.07 per share loss) in Q1 2025.
• Cash Runway: As of March 31, 2026, Vaxart held cash, cash equivalents, and short-term investments of $61.0 million. Management stated that this cash balance provides an operational runway extending into the second quarter of 2027. This timeline is critical, as it guarantees Vaxart has enough capital to reach the primary Phase 2b COVID-19 efficacy and safety readouts expected in late 2026/early 2027 without needing to execute a highly dilutive public share offering in the immediate future.
• Alternative Financing: To further bolster its flexibility, Vaxart entered into a $25 million share purchase agreement with Lincoln Park Capital in April 2026. This facility grants Vaxart the sole discretion to sell shares over a 24-month period, providing a tactical backstop if they require quick cash injections.

The July 2026 Proxy Contest: Corporate Governance Under Scrutiny

Beyond clinical trials and balance sheets, Vaxart is currently embroiled in a major corporate governance battle that could reshape its strategic direction.

On May 19, 2026, Vaxart filed preliminary proxy materials with the SEC in anticipation of its upcoming Annual Meeting of Stockholders on July 16, 2026. Alongside this filing, the company issued an urgent open letter to its shareholders. The board is currently facing a contested election against a group of dissident shareholders who have nominated three alternative director candidates.

The board’s campaign emphasizes the need for stability and expert leadership at this "critical strategic juncture." Vaxart is pushing for the reelection of its six director nominees, which includes newly appointed Dr. James Breitmeyer, an industry veteran with over 35 years of clinical and regulatory vaccine experience.

For investors of VXRT stock, this proxy contest is a critical event to monitor. Dissident shareholder groups typically push for aggressive cost-cutting, immediate monetization of intellectual property, or even a sale of the company. On the other hand, the current management team under CEO Steven Lo remains focused on realizing the long-term value of the VAAST platform by hitting their clinical milestones and securing further partnerships. The outcome of the July 16 vote could cause significant volatility in the stock price depending on which faction emerges victorious.

Is VXRT Stock a Buy, Sell, or Hold? The Investment Thesis

So, what does this mean for the investment thesis of VXRT stock?

The Bull Case

• Pioneering Technology: An oral pill vaccine is the holy grail of global health distribution. If Vaxart's VXA-CoV2-3.3 shows comparable or superior efficacy to injectable mRNA vaccines in the upcoming Phase 2b readout, it will completely validate the VAAST platform, immediately making Vaxart an attractive acquisition target for major pharma players.
• Validated Program & Funding: The $218.9M BARDA funding and the Dynavax partnership provide massive non-dilutive validation and cash support.
• First-in-Class Norovirus Potential: With HilleVax out and Moderna experiencing delays, Vaxart holds the strongest mucosal norovirus clinical dataset.
• Undervalued Relative to Analyst Targets: Wall Street analysts currently hold an average 12-month price target of approximately $4.00 for VXRT stock (ranging from a conservative $2.00 to an optimistic $8.00). Compared to the current trading price of ~$0.61, this represents massive theoretical upside.

The Bear Case

• OTCQX Trading Constraints: The loss of the Nasdaq listing restricts institutional access, which can cap the stock's short-to-medium-term upward momentum and increase retail volatility.
• Execution and Clinical Risk: Biotech history is filled with candidates that looked spectacular in Phase 1 and 2 but failed to show statistical significance in larger Phase 2b or Phase 3 trials. If the ~5,000-person cohort trial fails to show efficacy against mRNA, the platform's value will crater.
• Funding Dependencies: While the runway extends to Q2 2027, Vaxart still needs massive capital to initiate a Phase 3 Norovirus trial. Without a major partnership, further dilution via the Lincoln Park Capital agreement or another public offering will be inevitable.

Verdict

VXRT stock is a classic high-beta, clinical-stage biotech play. It is not suitable for risk-averse investors or those looking for steady capital preservation. However, for speculative investors with high risk tolerance, the current sub-$1.00 price offers an asymmetric risk-reward profile. The next 6 to 12 months will bring binary, make-or-break clinical readouts that will either propel VXRT stock to multiples of its current value or cement its place as an unfulfilled scientific promise.

Frequently Asked Questions (FAQ)

Why was Vaxart (VXRT) delisted from Nasdaq?

Vaxart was delisted from Nasdaq on July 8, 2025, because its share price fell below the minimum $1.00 bid price requirement specified under Nasdaq Listing Rule 5550(a)(2). The company subsequently transitioned to the OTCQX Best Market to ensure continued trading.

Where is VXRT stock currently traded?

VXRT stock is currently traded on the OTCQX Best Market, the highest and most transparent tier of the Over-The-Counter Markets Group. It continues to trade under the ticker symbol VXRT.

When will Vaxart release clinical trial results?

Vaxart is expected to release 12-month safety and immunogenicity data from the 400-person sentinel cohort of its Phase 2b COVID-19 trial in early Q2 2026. The full comparative primary efficacy and safety readout from the main cohort of approximately 5,000 participants is anticipated in late 2026 or early 2027.

Does Vaxart have enough cash to fund its operations?

Yes, as of March 31, 2026, Vaxart had $61.0 million in cash, cash equivalents, and investments. This capital provides an operating runway into the second quarter of 2027, covering the expected timeline for its major COVID-19 clinical trial readouts.

Who are Vaxart's primary competitors in the norovirus vaccine market?

Following the clinical failure of HilleVax in 2024, Vaxart's main competitor is Moderna, which is developing an mRNA-based norovirus vaccine (mRNA-1403). However, Moderna's program has faced clinical holds and trial delays, giving Vaxart's oral candidate a competitive advantage.